Inventor(s): Elizabeth Gaillard, James Dillon
Abstract
The glutathione mimic prodrug is used to administer phosphorylated derivatives as antioxidants for disease prevention and treatment. Targeted diseases include ocular disorders, HIV/AIDS, inflammatory bowel disease, colitis, general aging, and arterial ischemic stroke, various types of cancers, asthma, sickle cell disease, Parkinson’s disease, and Alzheimer’s disease, among many others. Glutathione mimics are also effective as radiation protectors allowing healthy tissue to be spared radiation damage during cancer treatment.
Potential commercial use and users:
Pharmaceutical companies, veterinary clinics
Advantages:
Glutathione mimic prodrugs are more effective than currently available pharmaceutical products with the elimination of unwanted metabolism, and are virtually non-toxic because they are natural product derivatives. The prodrugs target specific cells or tissues for therapeutic purposes and allow for much higher doses of radiation to be used in radiation therapy treatment due to the enhanced protective effect to healthy tissue. The compounds can be administered orally, subcutaneously or parenterally and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds are effective for all warm-blooded animals, in particular mammals, including humans.
Status: Patent Pending
Contact Us